Since the time you follow us on Croblanc, you are beginning to be used to hear about the Youtube channel Bloomberg Television, and its viral videos that are always talked about on the web, and even beyond! That's why we're telling you about it today, because this new video might pique your interest.
To watch the video Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial that was posted today by the Youtube channel Bloomberg Television, click on the video just above. You will then be able to discover it in streaming for free directly on our site!
This video is currently making the buzz on the internet and may end up in the Youtube trends. It was published a few hours ago by the videographer of the Youtube channel Bloomberg Television who regularly publishes videos similar to the content we are talking about today.
Sometimes when we watch a video on the internet, we can have some feedback to give to the content creator. To tell him about a problem or an error that we discovered for example. First solution to contact the author of this video is on Youtube: Try to find his email address in "About". If you don't get an answer, you can try again to contact him but on another platform. Twitter seems to be a pretty easy way to contact a Youtuber about one of his contents.
We are almost at the end of the news about the video Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial, all the team Croblanc hopes that you found it interesting to read. In our platform, you can find other videos of Bloomberg Television, take a look at it occasionally, it's practical and it can allow you to find contents that you had never seen before on the web!
Friends, this is already the end of this little editorial, see you soon for a new article on Croblanc!
For your information, you can find below the description of the video Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial published by the Youtube channel Bloomberg Television:
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke about the results on "Bloomberg Open Interest."
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more.
Connect with Bloomberg Television on:
X: https://twitter.com/BloombergTV
Facebook: https://www.facebook.com/BloombergTelevision
Instagram: https://www.instagram.com/bloombergtv/
Connect with Bloomberg Business on:
X: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/
TikTok: https://www.tiktok.com/@bloombergbusiness?lang=en
Reddit: https://www.reddit.com/r/bloomberg/
LinkedIn: https://www.linkedin.com/company/bloomberg-news/
More from Bloomberg:
Bloomberg Radio: https://twitter.com/BloombergRadio
Bloomberg Surveillance: https://twitter.com/bsurveillance
Bloomberg Politics: https://twitter.com/bpolitics
Bloomberg Originals: https://twitter.com/bbgoriginals
Watch more on YouTube:
Bloomberg Technology: https://www.youtube.com/@BloombergTechnology
Bloomberg Originals: https://www.youtube.com/@business
Bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake
Bloomberg Espanol: https://www.youtube.com/@bloomberg_espanol
Bloomberg Podcasts: https://www.youtube.com/@BloombergPodcasts